Ferguson Wellman Capital Management Inc. boosted its holdings in shares of Stryker Corporation (NYSE: SYK) by 0.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 180,039 shares of the medical technology company's stock after acquiring an additional 1,374 shares during the
Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers despite sector-wide derating risks. Key growth drivers include Mako's continued share gains in major joints, expansion into extremities, and under-tapped potential in ambulatory surgical centers. Management prioritizes M&A for capital allocation, targeting complementary technologies in robotics, cardiology, and urology, while organic growth opportunities like Smart Care add upside.
DSM Capital Partners LLC boosted its stake in shares of Stryker Corporation (NYSE: SYK) by 315.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,731 shares of the medical technology company's stock after acquiring an additional 14,225 shares
Cerity Partners LLC increased its holdings in Stryker Corporation (NYSE: SYK) by 1.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 317,999 shares of the medical technology company's stock after acquiring an additional 3,419 shares during the
First Merchants Corp lowered its position in Stryker Corporation (NYSE: SYK) by 2.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 56,054 shares of the medical technology company's stock after selling 1,637 shares during the period. First Merchants Corp's
Does a 10% growth rate justify a 46x earnings stock price?
NEW YORK--(BUSINESS WIRE)--VB Spine completes the acquisition of Stryker's Cestas, France spinal implant manufacturing facility.
Pre-Market Stock Futures: The futures are little changed after a blockbuster day to open the first full trading week of 2026. The combination of no Santa Claus rally, the market shrugging off the capture of Venezuelan dictator Maduro, then embracing the action, plus some big pent-up money sitting on the sidelines, all helped to propel... Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, CoreWeave, Digital Realty, Palantir Technologies, ServiceNow, Shopify, SoFi Technologies, and More.
Chicago Capital LLC trimmed its position in Stryker Corporation (NYSE: SYK) by 0.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 195,621 shares of the medical technology company's stock after selling 1,773 shares during the period. Stryker comprises 1.8% of Chicago Capital LLC's investment
Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's fourth quarter and full year that ended December 31, 2025.
Asset Management One Co. Ltd. boosted its stake in shares of Stryker Corporation (NYSE: SYK) by 1.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,696 shares of the medical technology company's stock after acquiring an additional 1,625 shares during the
Capital Advisors Inc. OK grew its stake in Stryker Corporation (NYSE: SYK) by 6.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 164,288 shares of the medical technology company's stock after purchasing an additional 9,257 shares during the period. Capital
Bank Pictet and Cie Europe AG lessened its holdings in Stryker Corporation (NYSE: SYK) by 1.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 145,097 shares of the medical technology company's stock after selling 2,268 shares during the period. Stryker
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Diversified Trust Co increased its position in shares of Stryker Corporation (NYSE: SYK) by 45.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,445 shares of the medical technology company's stock after purchasing an additional 3,899 shares during the
GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) and Stryker (NYSE: SYK - Get Free Report) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations. Risk and Volatility GE HealthCare Technologies has
Boston Trust Walden Corp lowered its position in Stryker Corporation (NYSE: SYK) by 7.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 287,909 shares of the medical technology company's stock after selling 21,926 shares during the quarter.
Carnegie Investment Counsel grew its holdings in shares of Stryker Corporation (NYSE: SYK) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 210,726 shares of the medical technology company's stock after acquiring an additional 3,752 shares during
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
This basket of 64 medical device stocks could raise its dividend for decades.